MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

OraSure Technologies Inc

Slēgts

SektorsVeselības aprūpe

3.22 -4.17

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.21

Max

3.36

Galvenie mērījumi

By Trading Economics

Ienākumi

-6.3M

-11M

Pārdošana

-227K

37K

P/E

Sektora vidējais

26.6

63.778

EPS

-0.06

Peļņas marža

-28,826.279

Darbinieki

501

EBITDA

-3.9M

-9.9M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+78.04% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-41M

257M

Iepriekšējā atvēršanas cena

7.39

Iepriekšējā slēgšanas cena

3.22

Ziņu noskaņojums

By Acuity

50%

50%

180 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

OraSure Technologies Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. apr. 23:55 UTC

Karstas akcijas

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2025. g. 2. apr. 22:50 UTC

Galvenie tirgus virzītāji

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2025. g. 2. apr. 21:08 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2025. g. 2. apr. 21:00 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2025. g. 2. apr. 23:56 UTC

Tirgus saruna

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2025. g. 2. apr. 23:44 UTC

Top Ziņas

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2025. g. 2. apr. 23:10 UTC

Tirgus saruna

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:57 UTC

Tirgus saruna

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2025. g. 2. apr. 22:43 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2025. g. 2. apr. 22:12 UTC

Tirgus saruna

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2025. g. 2. apr. 21:48 UTC

Top Ziņas

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2025. g. 2. apr. 21:41 UTC

Tirgus saruna

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2025. g. 2. apr. 21:04 UTC

Top Ziņas

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2025. g. 2. apr. 21:03 UTC

Tirgus saruna

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2025. g. 2. apr. 20:53 UTC

Peļņas

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2025. g. 2. apr. 20:52 UTC

Peļņas

Kaiser Aluminum Changes Inventory Acctg Methodology

Salīdzinājums

Cenas izmaiņa

OraSure Technologies Inc Prognoze

Cenas mērķis

By TipRanks

78.04% augšup

Prognoze 12 mēnešiem

Vidējais 6 USD  78.04%

Augstākais 6 USD

Zemākais 6 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi OraSure Technologies Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

3.3 / 3.39Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

180 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par OraSure Technologies Inc

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.